Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Kairos Pharma, LTD. on September 14, 2026. The report discloses a Regulation FD event involving the release of a new investor presentation. The presentation was issued for the H.C. Wainwright 28th Annual Global Investment Conference, held in New York, NY from September 14-16, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate communications rather than financial performance data.
Material Changes
No material financial changes versus prior periods are reported in this document. The primary event is the dissemination of updated information regarding the Company's clinical program and activities.
Guidance, Outlook, and Management Commentary
- Management Action: Chief Executive Officer John Yu presented an update on the Company's clinical program and activities at the H.C. Wainwright conference.
- Investor Presentation: A new investor presentation was issued and is available on the Company's website (www.kairospharma.com).
- Legal Status: The information in this Item 7.01 and the accompanying Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Exchange Act. It is not incorporated by reference into other Company filings.
Key Facts for Investor Verification
- Verify the content of the investor presentation (Exhibit 99.1) for specific clinical trial updates.
- Confirm the presentation is accessible via the Company's official website.
- Note that the Company is classified as an emerging growth company.
- Recognize that this filing does not contain audited financial statements or forward-looking financial guidance.